Monika Mandecka
Polish Academy of Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Monika Mandecka.
Folia Neuropathologica | 2016
Marta Nesteruk; Tomasz Nesteruk; Maria Styczyńska; Monika Mandecka; Anna Barczak; Maria Barcikowska
INTRODUCTION The aim of our study was to evaluate the usefulness of several biomarkers in predicting the conversion of mild cognitive impairment (MCI) to Alzheimers disease (AD): β-amyloid and tau proteins in cerebrospinal fluid and the volumetric evaluation of brain structures including the hippocampus in magnetic resonance imaging (MRI). MATERIAL AND METHODS MRI of the brain with the volumetric assessment of hippocampus, entorhinal cortex, posterior cingulate gyrus, parahippocampal gyrus, superior, medial and inferior temporal gyri was performed in 40 patients diagnosed with mild cognitive impairment. Each patient had a lumbar puncture to evaluate β-amyloid and tau protein (total and phosphorylated) levels in the cerebrospinal fluid. The observation period was 2 years. RESULTS Amongst 40 patients with MCI, 9 (22.5%) converted to AD within 2 years of observation. Discriminant analysis was conducted and sensitivity for MCI conversion to AD on the basis of volumetric measurements was 88.9% and specificity 90.3%; on the basis of β-amyloid and total tau, sensitivity was 77.8% and specificity 83.9%. The combined use of the results of volumetric measurements with the results of proteins in the cerebrospinal fluid did not increase the sensitivity (88.9%) but increased specificity to 96.8% and the percentage of correct classification to 95%.
Journal of Alzheimer's Disease | 2016
Monika Mandecka; Magdalena Budziszewska; Anna Barczak; Beata Peplonska; Małgorzata Chodakowska-Żebrowska; Anna Filipek-Gliszczynska; Marta Nesteruk; Maria Styczyńska; Maria Barcikowska; Tomasz Gabryelewicz
In the course of Alzheimers disease (AD), early pathological changes in the brain start decades before any clinical manifestation. The concentration levels of AD cerebrospinal fluid (CSF) biomarkers, such as amyloid-β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau), may reflect a cerebral pathology facilitating an early diagnosis of the disease and predicting a cognitive deterioration. The aim of this study was to estimate the prevalence of AD CSF biomarkers in those individuals with a subjective cognitive decline (SCD), a mild cognitive impairment (MCI), and Alzheimers dementia (AD-D), together with the relationships between the biomarkers, an APOE ɛ4 presence, and a verbal episodic memory performance. We included 252 patients from the memory clinic with a diagnosis of SCD (n = 85), MCI (n = 87), and AD-D (n = 80). A verbal episodic memory performance level was assessed and was based on a delayed recall trial from the 10-word list of an auditory verbal learning task (AVLT). We found that the patients with more severe cognitive impairments had significantly lower levels of Aβ1-42 and higher levels of T-tau and P-tau. This pattern was also typical for the APOE ɛ4 carriers, who had lower levels of Aβ1-42 than the noncarriers in the AD-D and MCI groups. The levels of T-tau and P-tau were significantly higher in the APOE ɛ4 carriers than in the noncarriers, but only in the MCI patients. The AVLT performance in the whole study samples was predicted by age, Aβ1-42, and the T-tau CSF biomarkers, but not by the APOE genotyping.
Neurologia I Neurochirurgia Polska | 2015
Marta Nesteruk; Tomasz Nesteruk; Maria Styczyńska; Anna Barczak; Monika Mandecka; Jerzy Walecki; Maria Barcikowska-Kotowicz
INTRODUCTION Mild cognitive impairment (MCI) is defined as abnormal cognitive state, but does not meet the criteria for the diagnosis of dementia. According to the new guidelines Alzheimers disease (AD) involves not only dementias phase but also predementia phase which is asymptomatic and pathological process in the brain is already present. For this reason it is very important to determine the suitability of markers which should be positive before onset of the first symptoms. One of these biomarkers is a structural magnetic resonance imaging with hippocampal volumetric assessment. The aim of this study was to investigate the usefulness of structural brain magnetic resonance imaging with volumetric assessment of the hippocampus and entorhinal cortex, posterior cingulate gyrus, parahippocampal gyrus, temporal gyri: superior, medial and inferior, to predict the conversion of MCI to AD. MATERIAL AND METHODS Magnetic resonance imaging of brain was performed at the baseline visit in 101 patients diagnosed with MCI. Clinic follow-ups were scheduled after 6.12 and 24 months. RESULTS Amongst 101 patients with MCI, 17 (16.8%) converted into AD within two years of observation. All measured volumes were lower in converters than non-converters. Discriminant analysis was conducted and sensitivity for MCI conversion to AD was 64.7%, specificity 96.4%. 91% of patients were correctly classified (converter or non-converter). CONCLUSIONS Volumetric measurements may help clinicians to predict MCI conversion to AD but due to low sensitivity it cannot be use separately. The study group requires further observation.
Amyotrophic Lateral Sclerosis | 2018
Beata Peplonska; Mariusz Berdynski; Monika Mandecka; Anna Barczak; Magdalena Kuzma-Kozakiewicz; Maria Barcikowska; Cezary Zekanowski
Abstract Activation of the TREM2 receptor on microglia stimulates phagocytosis and decreases the microglial proinflammatory response. Mutations in exon 2 of the TREM2 gene have been reported to be associated with various neurodegenerative diseases characterized by chronic inflammation. The aim of our study was to evaluate exon 2 of TREM2 gene variants as a putative genetic risk factor for Alzheimer’s disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) in the Polish population. The results were interpreted using previously published data, especially highlighting differences in the prevalence of the variants among Caucasian subpopulations across different geographic regions. The DNA sequence of exon 2 of TREM2 was analyzed in 811 subjects (274 AD, 135 FTD, 194 ALS patients, and 208 neurologically healthy controls). Nine heterozygous variants were detected, including two novel ones: p.G29 = and c.41-2_3insA, found respectively in a control and an ALS patient. Additionally, we identified one homozygous and two compound heterozygous FTD patients. We confirm previous data that homozygous and compound heterozygous TREM2 mutations can be causative for FTD.
Polish Journal of Radiology | 2017
Krzysztof Jaworski; Maria Styczyńska; Monika Mandecka; Jerzy Walecki; Dariusz A. Kosior
Summary Fahr syndrome is a rare neurodegenerative disorder characterized by symmetrical, bilateral calcifications in the basal ganglia, nucleus gyrus and cerebral cortex. The continuous advancement as well as widespread use of brain imaging have contributed to the increasing detection rates of such changes. Nevertheless, their etiology is understood only partially and the methods of causative treatment are limited. Due to various symptoms, Fahr syndrome may resemble diseases from the field of neurology, psychiatry, cardiology and even urology. This article provides an up-to-date review of the literature concerning Fahr syndrome in terms of clinical practice.
Folia Neuropathologica | 2018
Anna Filipek-Gliszczynska; Anna Barczak; Magdalena Budziszewska; Monika Mandecka; Tomasz Gabryelewicz; Maria Barcikowska
Case Study and Case Report | 2015
Marta Nesteruk; Tomasz Nesteruk; Monika Mandecka; Ma; gorzata Dorobek
Alzheimers & Dementia | 2015
Monika Mandecka; Barczak Anna; Magda Budziszewska; Maria Styczyńska; Maria Barcikowska; Tomasz Gabryelewicz
Postępy Nauk Medycznych | 2013
Anna Barczak; Tomasz Gabryelewicz; Bogusław Wasiak; Maciej P. Golan; Małgorzata Chodakowska-Żebrowska; Anna Pfeffer; Maria Styczyńska; Monika Mandecka; Maria Barcikowska
Archive | 2013
Anna Barczak; Tomasz Gabryelewicz; Maciej P. Golan; Anna Pfeffer; Maria Styczyńska; Monika Mandecka; Maria Barcikowska